Long-term (three-year) prognosis of patients treated with reperfusion or conservatively after acute myocardial infarction

Gottlieb, Shmuel; Boyko, Valentina; Harpaz, David; Hod, Hanoch; Cohen, Miriam; Mandelzweig, Lori; Khoury, Zahi; Stern, Shlomo; Behar, Solomon

doi:10.1016/s0735-1097(99)00152-7

Cited by 21 publications

(15 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The validity of this finding persists after controlling for age and additional confounding variables. Our results are in accord with other observational studies [13, 17, 19]. Koenig et al [13]reported an extended benefit of thrombolytic therapy on long-term (mean 4.4 years) survival in approximately 1,200 nondiabetic patients aged 25–74 years who had survived a first Q-wave AMI for at least 28 days.…”

Section: Discussionsupporting

confidence: 92%

“…The most commonly chosen parameters for conducting these evaluations are age, gender, concomitant disease, AMI type, localization and severity, drug therapy as well as the role played by thrombolysis. Controlled clinical studies on the efficacy of thrombolysis in AMI patients have been given major attention [7, 11, 12, 13, 14, 15, 16, 17]. For the most part, these studies were conducted on selective samples according to strict exclusion and eligibility criteria.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Long-Term Mortality Rates Reflect Progressive Prognostic Benefits of Thrombolysis in Patients with First Acute Myocardial Infarction

Shapira

Pines²,

Goldbourt

et al. 2000

Cardiology

View full text Add to dashboard Cite

This community nonrandomized study comprised a consecutive cohort of 1,545 (81% males) ≤65-year-old patients who survived a first acute myocardial infarction (AMI). The all-cause 4- to 5-year mortality rate was 9% (80% cardiac). Univariate analysis revealed that older age, female gender, hypertension, diabetes, not undergoing thrombolysis, higher Killip class, preinfarction heart disease, peripheral vascular disease (PVD) and chronic obstructive lung disease (COLD) were significantly associated with increased mortality. Multivariate analyses disclosed the latter five parameters as being independent predictors of mortality. Our results show that patients undergoing thrombolysis enjoyed a progressive prognostic benefit over time. The independent contribution of PVD and COLD to long-term mortality is highlighted, in addition to the contribution of thrombolytic therapy, Killip class, and heart disease prior to infarction as being important predictors of long-term mortality in patients with a first AMI.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Long-Term Mortality Rates Reflect Progressive Prognostic Benefits of Thrombolysis in Patients with First Acute Myocardial Infarction

Shapira

Pines²,

Goldbourt

et al. 2000

Cardiology

View full text Add to dashboard Cite

show abstract

“…34,35 Augmentation or restoration of endothelial PDGF-AB-dependent proangiogenic pathways can reduce the size of infarct size after experimental coronary artery occlusion. The clinical translation of these findings will require future studies aimed at defining and potentially expanding the therapeutic window of this approach, testing under transient and chronic hypoxic conditions, and using relevant disease models that enhance the vascular pathology in the aging heart (eg, hypertension, diabetes, and hyperlipidemia).…”

Section: Restoration Of Angiogenic Potentialmentioning

confidence: 99%

Platelet-Derived Growth Factor-AB Limits the Extent of Myocardial Infarction in a Rat Model

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Also, in the United States, [3][4][5][6][7][8][9][10][11] Australia, 12) Canada, 13) the United Kingdom, [14][15][16][17] France, [18][19][20] Switzerland, 21,22) Israel, 23,24) Austria, 25) Spain, 26) Portugal, [27][28][29] Italy, [30][31][32] Finland, 33) Sweden, 34) Germany, [35][36][37][38][39] Denmark, 40,41) the Netherlands [42][43][44] and in Belgium, [45][46][47] there is controversy about the preferential use of thrombolytics and/or rescue PTCA and stenting. Up to now it is not known which therapy provides the best results in the longterm with total patency or TIMI 3 patency.…”

mentioning

confidence: 99%

Changes in Mortality of Acute Myocardial Infarction as a Function of a Changing Treatment during the last Two Decades

Claessens

et al. 2000

Jpn Heart J

View full text Add to dashboard Cite

SUMMARYForty years ago, after the establishment of coronary care units, a significant decrease in mortality of acute myocardial infarction was noted. Twenty years ago, the breakthrough of thrombolysis realized once again a significant decrease in mortality. In this study we compare, in a rather small community hospital, the mortality and safety of thrombolytic therapy in acute myocardial infarction with a more conventional, conservative medical therapy.We examined all cases of acute myocardial infarction between 1978 up to 1998 inclusive, concerning treatment and mortality rate after a six month period. To be included in the study, acute myocardial infarction had to fulfill particular inclusion criteria. A total of 1863 cases of acute myocardial infarction were included.The mortality rate of patients with acute myocardial infarction treated with thrombolytic agents was strikingly lower and statistically very significantly different (p < 0.001) in comparison with the mortality rate of patients treated with heparin or coumarine derivatives.The mortality rate dropped from 10.57% in the coumarine group and from 14.95% in the heparin group to 5.41% in the alteplase group, to 4.95% in the anistreplase group and 4.00% in the streptokinase subgroup.The complications directly connected to the treatment did not seem to be different between the five groups, and they were also not more frequent by using thrombolytic agents.In the last 20 years, better preventive measures (life habits, diet, medication) and trials to better control the risk factors have not influenced greatly the average amount of cholesterol in patients with an acute myocardial infarction. Also the percentage of patients with high blood pressure has hardly decreased over the last 20 years.The mortality associated with acute myocardial infarction has decreased significantly with the use of thrombolytics. In most cases, thrombolytics are administered routinely and safely. In this way, they are the first choice therapy for myocardial infarction in smaller hospitals.

show abstract

Long-term (three-year) prognosis of patients treated with reperfusion or conservatively after acute myocardial infarction

Abstract: This survey demonstrates the extent of implementation in daily practice of ART and ICP and their impact on early and long-term prognosis in an unselected population after AMI.

Cited by 21 publications

References 59 publications

Long-Term Mortality Rates Reflect Progressive Prognostic Benefits of Thrombolysis in Patients with First Acute Myocardial Infarction

Long-Term Mortality Rates Reflect Progressive Prognostic Benefits of Thrombolysis in Patients with First Acute Myocardial Infarction

Platelet-Derived Growth Factor-AB Limits the Extent of Myocardial Infarction in a Rat Model

Changes in Mortality of Acute Myocardial Infarction as a Function of a Changing Treatment during the last Two Decades

Contact Info

Product

Resources

About